Centre Hospitalier De La Cote Basque — Clinical Trial Site

174 Registered trials

81 Currently recruiting

Organisation

Centre Hospitalier De La Cote Basque

Location

Bayonne, France

Identifier

ORG-100041218

Address

13 Avenue Interne Jacques Loeb, 64100, France

Departments

1016:Neurologie
1209: Hématologie Clinique
125004: Service Hématologie
211:Service Hématologie
Cardiology
Departement de Cardiologie
Dermatology
Digestive Oncology
gastro enterology
gastro oncology
Gastro-entérologie
gastroentérologie
gastroenterology
Haematology
Hematologgy
Hématologie
Hematology
Hematology Department
Hepato gastro enterology
Hépato Gastro et Entérologie
Hepato-Gastro-Entérology
Hepatogastroenterology
Maladies Infectieuses et Tropicales
Medical Oncology
Medical Pneumology
N/A
Nephrology and Dialysis Department
Neurologie
Neurology
ONCOLOGIE
Oncologie Médicale
Oncology
Oncology Department
Penumologie
Pneumologie
Pneumologie médicale
Pneumology
Pneumology Oncology
Radiology Diagnostique
Rhumatologie
Satellite site Oncology Department
Service d'hématologie
Service d'hématologie - Maladies du sang
Service d'oncologie medicale
Service d’Hématologie
Service d’Hématologie Clinique
Service d’Hématologie et maladies du sang
Service de cardiologie
Service de Gastroenterologie
Service de neurologie, Centre hospitalier de la Côte Basque
Service de Pneumologie
Service hématologie
Service neurologie
Service Oncologie
Service Pneumologie
Service Recherche Clinique
Urgences / SAMU/ SMUR

Clinical trials at this site (174)

Search interface

Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizu… Recruiting

2024-515788-73-00 MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCE 4 2024-07-30
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
EstroTEP and circulating biomarkers for ER-positive HER2-negative metastatic breast cancer patients Recruiting

2023-506282-66-00 Women with ER+ HER2- metastatic breast cancer who progr 5 2024-05-27
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
A clinical trial comparing a new treatment (MK-5684) to approved medication for advanced prostate cancer after prior hormonal therapy and ch… Recruiting

2023-504899-25-00 Metastatic castration resistant prostate cancer 5 2024-04-04
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab … Recruiting

2022-501554-11-00 Patients with previously untreated Richter’s syndrome ( 4 2024-03-21
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting

2022-502046-28-00 HER2-Positive, PIK3CA Mutated, Locally Advanced or Meta 5 2023-12-22
A Phase 2 Study of Teclistamab in Combination with Daratumumab or Lenalidomide in Elderly Patients with Newly Diagnosed Multiple Myeloma - I… Recruiting

2024-514101-65-00 Multiple Myeloma 4 2023-12-21
Study evaluating thromboprophylaxis in patients with advanced germ cell tumours of good or intermediate prognosis Recruiting

2022-502426-41-00 Thromboprophylaxis in good and intermediate prognosis a 5 2023-10-17
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
MARSUN: Evaluation of the benefits of the combination of Mosunetuzumab-Lenalidomide versus a treatment chosen by the investigator in Patient… Recruiting

2022-501810-77-00 Relapsed or Refractory Marginal Zone Lymphoma 5 2023-09-01
A Study of Subcutaneous Nivolumab + Relatlimab FDC in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-127) Recruiting

2022-500967-11-00 Previously Untreated Metastatic or Unresectable Melanom 5 2023-07-06
Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterre… Recruiting

2024-514952-34-00 Catheter related bloodstream infections due to Staphylo 5 2023-06-23
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Peripheral T-cell lymphoma (PTCL) 6 2023-06-07
RIISC Recruiting

2024-513669-38-00 Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis 5 2023-05-17
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting

2023-503481-23-00 Maintenance treatment in metastatic non-squamous lung c 5 2023-03-20
Preventive effect of Clopidogrel on the systemic sclerosis development risk Recruiting

2024-511005-39-00 Raynaud phenomenon 10 2022-06-22
A randomized phase I/ II multicenter study evaluating combination of luspatercept in LR-MDS without RS having failed or being ineligible to … Recruiting

2024-515354-24-00 Low risk myelodysplastic syndrom without RS having fail 9 2022-05-18
Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting

2022-502425-18-00 Adenocarcinoma of the prostate 5 2022-04-19
IFM2020-05-BENEFIT-Multicenter Open label Phase 3 study of Isatuximab plus Lenalidomide and Dexamethasone with/without Bortezomib in the Tre… Recruiting

2024-517215-67-00 Newly diagnosed Non-Frail transplant Ineligible Multipl 5 2021-06-11
A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma Recruiting

2024-516181-11-00 RELAPSE/REFRACTORY B-CELL LYMPHOMA. 4 2021-06-10